Safety and efficacy of administering 0.2 mg of recombinant human TSH for two consecutive days as an adjuvant to low-dose radioiodine therapy in out-patients with large non-toxic multinodular goitre.

Recombinant human TSH (rhTSH) has recently been used as an adjuvant to the treatment of non-toxic multinodular goitre (MNG) by means of 131I. The aim of our study was to evaluate the efficacy of 0.2 mg rhTSH or placebo administered im on 2 consecutive days before a fixed therapeutic dose of 14 mCi of 131I. Thirteen elderly patients (71\ub17 years) with large non-toxic MNG (group 1) were treated with rhTSH plus 131I. While a control group of 8 patients, matched for age and non-toxic MNG volume, was treated with placebo plus 131I (group 2)